Download AmVac AG Strong Team and Renowned Advisors INVESTMENT HIGHLIGHTS Portfolio with exceptional potential

INVESTMENT HIGHLIGHTS
Portfolio with exceptional potential
•
Six promising vaccine candidates
•
AmVac AG
Founded
August 2005
Headquarters
Zug, Switzerland
Legal form
Joint stock company under Swiss law (privately held)
Share capital
CHF 689.635,67
•
Total funding
•
Strong Team and Renowned Advisors
Straightforward development plans with
Melinda-Kinga Karpati
Foundress AmVac AG, entrepreneur; longterm
advanced milestones to be reached in
CEO
experience in start-up management and corporate
development (medtech, biotech and IT industry)
the near future
•
•
Marie-Christine Kopkow
Attorney at Law, multiyear experience in commercial
Chairman of the Board
and Corporate Law and founding partner of a law
Dr. George Kavkasidze
Medical doctor, with academic degree of PhD;
Head of Marketing and
almost 20 years’ experience in biopharmaceutical
Business Development
Merck-Serono
•
Dr. Marian Wiegand
Vaccine expert with many years’ experience as
Head of R&D
scientist for Crucell and the Max Planck Institute of
Biochemistry
Ferenc Zimonyi
•
ship programs for mass-vaccination
Prof. Dr. Reinhard Glück
International vaccine expert, president of Swiss
Biotech Association
Prof. Dr. Carlos A. Guzmán
•
Head Vaccinology, Helmholtz Centre for Infectious
Diseases, Braunschweig/Germany
strategic investors
Prof. Dr. Wolfgang J.
Head Research Molecular Virology, Max Planck
Neubert
Institute of Biochemistry, Martinsried/Germany
Dr. med. Ladislav Prikler
Direction Uroviva, Centre of Urology in Bulach and
Clinic Hirslanden, Switzerland
BUSINESS STRATEGY
•
Exploit
•
Drive
•
Build
•
Move
TECHNOLOGY PLATFORMS
1.) Gynevac platform: Development of
2.) Sendai platform: New generation of
therapeutic vaccines against the most
prophylactic and therapeutic vaccines
frequent urogenital diseases
3.) MALP2 platform: New generation
reduced cost of goods
PIPELINE
PRODUCT
AMV602 (Sendai Platform)
INDICATION
STATUS
Gynecological infections, mainly bacterial vaginosis (BV) and trichomonads
Phase III
Other complications related to BV: preterm birth/HPV/HIV/ etc.
Preparation of Phase III
CP/BPH
Preparation of Phase III
Respiratory syncytial virus (RSV)
Preparation of Phase I
Preclinical
Preclinical
Preclinical
TARGET MARKETS
2.) Sendai-Platform
A) Benign prostate hyperplasia (BPH)
B) Bacterial vaginosis (BV)
C) Infections caused by respiratory
Global market volume around USD 4
Global market for BV-treatment around
syncytial virus (RSV)
billion BPH affects ~50 million men aged
USD 450 million, estimation for BV-
Target
over 50, and more than 33 million of
prevention over USD 1 billion
vaccination in seven major markets (e.g.
these men suffer from moderate to severe
population
for
preventive
US, Japan, EU) about 206 million people.
disease.
Recent Milestones
•
Gynevac-Platform: Decoding of Immuno-timulating “Mode of Action”
•
Strategic partnership with Medinserv for secondary packaging, marketing and distribution of AmVac’s Gynevac vaccine in the Caucasus,
Middle Asia and CIS regions
•
Establishment of a dedicated production facility and GMP-compliant manufacturing process for Gynevac in collaboration with Vakcina Kft.
•
Positive preclinical data supporting the potential of AmVac’s Sendai-based vaccine candidate for the prevention of infections caused by
respiratory syncytial virus (RSV)
•